Vitals Knowledge Vault

CagriSema

11 min read

CagriSema

aka Cagrilintide + Semaglutide coadministration Class Dual satiation pathway: long-acting amylin analog (cagrilintide) + GLP-1 receptor agonist (semaglutide) Regulatory status ⚠️ INVESTIGATIONAL — NOT FDA-APPROVED (as of April 2026)

TL;DR

CagriSema is the co-administration of cagrilintide 2.4 mg (investigational long-acting amylin analog) and semaglutide 2.4 mg (FDA-approved GLP-1 RA) as two separate weekly SC injections. REDEFINE-1 Phase 3 (n=3,417) showed −20.4% mean weight loss at 68 weeks vs −3.0% placebo — the highest Phase 3 monotherapy weight-loss result recorded (PMID 40544433). REDEFINE-2 in adults with obesity + T2D showed −13.7% weight loss and 73.5% achieved HbA1c ≤6.5% (PMID 40544432). CagriSema is not FDA-approved as of April 2026 — Novo Nordisk regulatory submission timing is uncertain post-2025 pipeline restructuring. The most important coaching flag: zero DXA/body composition data published — lean mass impact of amylin is completely unknown in humans.

⚠️ Investigational status prominent: Do not describe CagriSema as approved, available, or prescribed. Access is limited to clinical trials or compassionate use until FDA approval.

One-Line Coach Summary

CagriSema produces the highest Phase 3 obesity weight-loss result seen to date (−20.4%), adding amylin’s area postrema satiation pathway to semaglutide’s hypothalamic pathway. The 79.6% GI AE rate, dual-injection burden, unknown lean-mass impact, and uncertain regulatory timeline make it a second-line option for partial responders to semaglutide monotherapy.

Evidence Grade

Transclude of Evidence-Grade---High

Mechanism of Action

CagriSema engages two non-overlapping satiation pathways via two distinct receptor families:

Semaglutide (GLP-1 RA): Long-acting GLP-1 receptor agonist (~7-day half-life). Activates hypothalamic arcuate nucleus POMC/CART anorexigenic neurons; indirectly inhibits NPY/AgRP orexigenic neurons. Also delays gastric emptying via vagal afferents and stimulates glucose-dependent insulin secretion. Primary CNS site: hypothalamus. Full receptor biology in GLP-1 GIP Glucagon.

Cagrilintide (long-acting amylin analog): 37-amino acid lipitated amylin analog with ~7-day half-life (vs ~13 minutes for native amylin). Acts via amylin receptors (AMY1/2/3 = CTR + RAMP1/2/3 heterodimers) in the dorsal vagal complex (DVC) — specifically the area postrema (AP, outside the BBB) and nucleus of the solitary tract (NTS). The AP is the blood-brain barrier–deficient gateway through which circulating amylin analogs access DVC neurons (PMID 26071095). Cryo-EM structural basis: F23 on cagrilintide anchors at the TM bundle; C-terminal P37 contacts the receptor extracellular domain (PMID 40847076). Six Calcr-expressing DVC neuronal populations mapped in rodents; sustained weight-loss response linked to NTS Glu6.2 population (Calcr/Prlh) (PMC11760743).

Additivity confirmed: Phase 1b (PMID 33894838) showed −15.7% at 20 weeks for CagriSema vs −9.8% for semaglutide alone — confirms non-redundant pathways. The two receptors (AMY + GLP-1R) and partially distinct neural substrates (DVC/AP vs hypothalamus/NTS) produce approximately additive, not redundant, satiation.

Clinical Evidence Summary

REDEFINE-1 — Phase 3, Obesity Without Diabetes

PMID 40544433 | NCT05567796 | NEJM August 14, 2025

Armn (approx.)Weight change≥5% loss≥20% loss≥25% loss≥30% loss
CagriSema2,108−20.4%89.1%63.0%43.3%26.2%
Semaglutide alone~302Not published in primary————
Cagrilintide alone~302Not published in primary————
Placebo~705−3.0%26.4%~3%——

Primary result: −20.4% vs −3.0% placebo → Δ −17.3 pp (95% CI −18.1 to −16.6), P<0.001.

⚠️ Statistical caveat: The 21:3:3:7 randomization means monotherapy arms (n≈302 each) are severely underpowered for direct comparison with the CagriSema arm (n≈2,108). Between-arm differences for monotherapy comparison are statistically unreliable.

Blood pressure (secondary, PMID 41328546):

  • Systolic BP: −10.9 mmHg (CagriSema) vs −2.8 mmHg (placebo)
  • Diastolic BP: −5.4 mmHg vs −1.7 mmHg
  • BP target achieved: 63.0% vs 32.0%

GI adverse events: 79.6% (CagriSema) vs 39.9% (placebo) — nausea, vomiting, diarrhea, constipation, abdominal pain. Mainly mild-to-moderate and transient. 3.4% discontinued due to adverse events.

REDEFINE-2 — Phase 3, Obesity With T2D

PMID 40544432 | NCT05394519 | NEJM August 14, 2025

ArmWeight change≥5% lossHbA1c ≤6.5%GI AEs
CagriSema−13.7%73.5%73.5%72.5%
Placebo−3.4%15.9%15.9%34.4%

Glycemic control: 73.5% of CagriSema participants achieved HbA1c ≤6.5% vs 15.9% on placebo (P<0.001).

⚠️ Hypoglycemia risk: GLP-1 agonists increase hypoglycemia risk when combined with sulfonylureas or insulin. REDEFINE-2 participants on background diabetes medications required monitoring and dose adjustment of concomitant agents.

Phase 2 — Cagrilintide Monotherapy

PMID 34798060 | NCT03856047 | Lancet 2021

Dose-finding RCT, 706 adults with overweight/obesity, 26 weeks. Cagrilintide 4.5 mg −10.8% vs liraglutide 3.0 mg −9.0% (P=0.03), establishing Phase 3 dose selection.

Phase 1b Combination Study

PMID 33894838 | NCT03600480 | 2022

Multiple ascending dose, 96 participants, 20 weeks. Cagrilintide 1.2 mg + semaglutide 2.4 mg: −15.7% (SE 1.6%). Proof-of-concept for Phase 3 2.4 mg/2.4 mg dose.

Meta-Analysis

PMID 39676787 | Indian J Endocrinol Metab 2024

  • CagriSema vs semaglutide alone: MD −9.07% weight loss (95% CI −11.91 to −6.23), P<0.00001
  • Cagrilintide monotherapy vs GLP-1 monotherapy: MD −1.83%, P=0.11 (not significant)

⚠️ Heterogeneity caveat: I² = 96–98% — extremely high. The pooled effect estimate is statistically significant but clinically imprecise due to trial duration and population differences.

Network Meta-Analysis

PMID 38286487 | BMJ 2024 | Yao et al.

76 RCTs in T2D patients. CagriSema ranked highest: −14.03 kg vs placebo. Tirzepatide: −8.47 kg vs placebo. Semaglutide: −6.47 kg vs placebo.

⚠️ ⚠️ Indirect comparison only. No head-to-head RCT exists. Network meta-analysis ranking is sensitive to model assumptions. CagriSema cannot be described as “superior to tirzepatide” based on this analysis.

Evidence Boundary Table

ClaimEvidence LevelPMIDsCaveats
−20.4% weight loss (REDEFINE-1)Phase 3 RCT, confirmatory4054443368 weeks; treatment-policy estimand
−13.7% weight loss in T2D (REDEFINE-2)Phase 3 RCT, confirmatory40544432T2D population; 68 weeks
73.5% achieved HbA1c ≤6.5%Phase 3 RCT, confirmatory40544432T2D population only
−10.9/−5.4 mmHg BP reductionPhase 3 secondary endpoint41328546Secondary endpoint; not CVOT
79.6% GI adverse eventsPhase 3 RCT, confirmatory405444333.4% discontinued due to AEs
Amylin lean-mass preservationNot measured—Zero human DXA data; animal data only
Amylin food-noise reductionNot measured—Not a REDEFINE endpoint; animal models only
Tirzepatide superiority claimUnsupported—No head-to-head trial exists
CV outcomes (REDEFINE-3)Unknown—CVOT status uncertain post-2025 restructuring
PK drug-drug interactionNot published—Different clearance pathways; interaction unlikely but unconfirmed
Long-term safety (>68 weeks)Unknown—No data beyond 68 weeks
cagrilintide monotherapy at 68 weeksNot published—Phase 2: −10.8% at 26 weeks only

Safety and Coaching Flags

⚠️ Prominent Flags (Non-Negotiable)

FlagDetailSource
REG_INVESTIGATIONALCagriSema NOT FDA-approved; do not describe as approved/availableRegulatory status April 2026
NO_DXA_DATAZero body composition data from REDEFINE trials; lean mass impact completely unknownMonograph Section 8.4
FOOD_NOISE_NOT_MEASUREDAmylin’s effect on food noise NOT measured in any REDEFINE trial; do not claim food-noise reduction for amylin specificallyMonograph Section 8.5
NO_TIRZEPATIDE_SUPERIORITYNo head-to-head trial vs tirzepatide; do not claim CagriSema is superior to tirzepatideMonograph Section 8.2
LEAN_MASS_UNSUPPORTEDAmylin lean-mass preservation NOT proven in humans; do not claim amylin spares muscleMonograph Section 8.4

Clinical Safety Flags

FlagDetailSource
GI_AE_HIGH79.6% GI AEs in REDEFINE-1; proactive antiemetic protocol requiredPMID 40544433
ADHERENCE_BURDENTwo separate weekly SC injections; vs tirzepatide single injectionMonograph Section 9.3
THYROID_BOXED_WARNINGSemaglutide boxed warning: contraindicated in personal/family history of MTC or MEN2; cagrilintide likely sameSemaglutide label
HYPOGLYCEMIA_T2DIncreased hypoglycemia risk with sulfonylureas/insulin in T2D populationPMID 40544432
OSA_SCREENWeight loss of 15–20% substantially reduces OSA severity; STOP-BANG screening recommendedMonograph Section 9.6
CVOT_STATUS_UNKNOWNREDEFINE-3 CVOT status uncertain post-2025 Novo Nordisk restructuringMonograph Section 8.7

Coaching Guidance

⚠️ Human sign-off required before issuing any CagriSema coaching recommendations. CagriSema is investigational. Coaching should focus on education for patients who may be candidates once approved, or those on semaglutide monotherapy considering augmentation.

Patient Selection

Appropriate candidates:

  • Adults with BMI ≥30 or BMI ≥27 + ≥1 comorbidity, without T2D
  • Adults with BMI ≥27 and T2D (HbA1c 7–10%)
  • Partial responders to semaglutide 2.4 mg monotherapy seeking additional weight reduction
  • No contraindications: no personal/family history of MTC or MEN2; no active pancreatitis; not pregnant

Not appropriate as first-line when semaglutide or tirzepatide monotherapy is available and approved.

GI Tolerance Protocol

  1. Start slow: Follow label titration schedule strictly; do not accelerate
  2. Injection timing: Both injections on same day (different sites: abdomen + thigh) or spaced — patient preference
  3. Meal timing: Inject on empty stomach or small low-fat meal; avoid large high-fat meals on injection day
  4. Hydration: Emphasize adequate hydration — nausea worsened by dehydration
  5. Antiemetic support: Prophylactic ondansetron 4–8 mg 30 min before injection may be considered (off-label, with physician consult)
  6. When to pause: Vomiting >24 hours or inability to tolerate oral intake → contact prescribing physician
  7. GI AE timeline: Peak during dose escalation; typically resolve within 4–8 weeks of reaching maintenance dose

Adherence Strategy (Two-Injection Burden)

  1. Same-day administration: Both on same day reduces cognitive burden vs spreading across week
  2. Site rotation: Rotate injection sites weekly to reduce local reactions
  3. Reminder system: Phone alarm, calendar reminder, or Vitals app notification
  4. Needle-averse patients: Validate burden; discuss tirzepatide (single injection) or forforglipron (oral) as alternatives

BIA / Body Composition Monitoring

⚠️ No DXA data from REDEFINE. GLP-1 class: 25–40% of weight lost as fat-free mass. Amylin’s effect on this ratio is completely unknown. BIA scales estimate body composition with 3–8% error — trends are acceptable, but do not over-interpret “muscle mass” readings as evidence of lean-mass preservation.

  • Track weight, body fat %, muscle mass estimate, visceral fat rating
  • Do not claim amylin spares lean mass — unproven in humans
  • For accurate body composition: DEXA scan before and after (minimum 6-month interval)
  • Protein Intake GLP-1 Glucagon for protein intake protocol (1.8–2.2 g/kg actual body weight)
  • Resistance training 2–3x/week remains the only evidence-based lean-mass mitigation

Food Noise Guidance

⚠️ Not measured in REDEFINE. Amylin’s hypothesized food-noise reduction via mesolimbic pathways (VTA, NAc) is based on animal models only. Coaching script: “You may notice reduced appetite and fewer food thoughts — likely related to both the semaglutide and cagrilintide effects. We don’t have specific studies measuring food noise, but overall appetite suppression is well-documented.”

Comparative Landscape

AgentMechanismDosingWeight lossGI AEsUS Status
CagriSemaAMY + GLP-1R2.4+2.4 mg SC qw (×2)−20.4% (68 wk)79.6%❌ Investigational
Tirzepatide (Zepbound®)GIPR + GLP-1R5/10/15 mg SC qw−20.9% (72 wk)~70–75%✅ Approved
Semaglutide (Wegovy®)GLP-1R2.4 mg SC qw−14.9% (68 wk)~74%✅ Approved
RetatrutideGIPR + GLP-1R + GCGR2–12 mg SC qw−24.2% (48 wk)High❌ Phase 3
ForforglipronGLP-1R (oral)15/45 mg daily−15.4% (36 wk)GI AEs❌ Investigational

⚠️ No head-to-head trials. All comparisons across different trials, populations, and durations. Do not state or imply CagriSema is “better than” or “equivalent to” tirzepatide without a head-to-head RCT.

Algorithm Hooks

def cagrisema_coaching_routing(user):
    """
    Vitals coaching routing for CagriSema (cagrilintide + semaglutide).
    CagriSema is NOT FDA-approved as of April 2026 — investigational only.
    """
    flags = []
 
    # ── Regulatory status gate ──────────────────────────────────────────
    if not user.is_clinical_trial_participant:
        flags.append("REG_INVESTIGATIONAL: CagriSema not FDA-approved; counsel patient on access via clinical trial or compounded equivalent")
 
    # ── GI adverse event risk ───────────────────────────────────────────
    if user.GI_AE_risk == "high":
        flags.append("GI_AE_HIGH: 79.6% GI AEs in REDEFINE-1; proactive antiemetic protocol recommended")
    else:
        flags.append("GI_AE_ROUTINE: start low, go slow on dose escalation")
 
    # ── Two-injection adherence ─────────────────────────────────────────
    if user.injection_burden_tolerance == "low":
        flags.append("ADHERENCE_BURDEN: two separate weekly SC injections required; consider tirzepatide or forforglipron as alternatives")
    else:
        flags.append("ADHERENCE_CONFIRMED: patient understands two-injection regimen")
 
    # ── T2D with CGM ───────────────────────────────────────────────────
    if user.has_T2D and user.has_CGM:
        flags.append("CGM_DIRECT: 73.5% achieved HbA1c ≤6.5% in REDEFINE-2; expect improved time-in-range")
    elif user.has_T2D and not user.has_CGM:
        flags.append("CGM_RECOMMEND: offer CGM for glycemic tracking in T2D population")
 
    # ── RHR proxy tracking ─────────────────────────────────────────────
    if user.has_wearable:
        flags.append("RHR_PROXY: semaglutide reduces RHR 2–4 bpm; CagriSema should match or exceed; track weekly")
    else:
        flags.append("RHR_NO_DATA: no wearable; manual pulse monitoring recommended")
 
    # ── Muscle preservation (Ben-specific flag) ───────────────────────
    if user.goal == "muscle_preservation":
        flags.append("LEAN_MASS_UNSUPPORTED: amylin lean-mass preservation NOT proven in humans; maintain protein intake + resistance training")
 
    # ── Food noise guidance ─────────────────────────────────────────────
    if user.reports_food_noise:
        flags.append("FOOD_NOISE_NOT_MEASURED: amylin's effect on food noise NOT demonstrated in trials; do not attribute food-noise reduction to amylin specifically")
 
    # ── OSA screening ───────────────────────────────────────────────────
    if user.BMI > 30 and not user.has_OSA_diagnosis:
        flags.append("OSA_SCREEN: STOP-BANG screening for obstructive sleep apnea before starting CagriSema")
 
    return flags

References

#PMIDCitationUsed For
140544433REDEFINE-1 Phase 3 (NEJM, Aug 2025)Primary efficacy, safety, trial design
240544432REDEFINE-2 Phase 3 (NEJM, Aug 2025)Primary efficacy in T2D, glycemic outcomes
334798060Cagrilintide Phase 2 dose-finding (Lancet, 2021)Monotherapy dose-response, safety
433894838Cagrilintide + semaglutide Phase 1b combination (2022)Combination proof-of-concept, PK
539676787Meta-analysis (Indian J Endocrinol Metab, 2024)CagriSema vs semaglutide comparison
638286487Network meta-analysis (BMJ, 2024)Comparative ranking among GLP-1 RAs
741328546Blood pressure outcomes from REDEFINE-1BP reduction secondary endpoint
840847076Cryo-EM amylin receptor structureMolecular mechanism of cagrilintide
926071095Hay et al. — Amylin receptor reviewComprehensive amylin pharmacology
1036883831Comprehensive amylin reviewAmylin biology, PK, mechanism
1139279639Cagrilintide QTc studyCardiac safety (QTc)
12PMC11760743DVC neuronal populations, cagrilintide mechanismNeural substrate mapping
13PMC10855385Amylin glucagon suppressionMetabolic effects of amylin

Vault note version: 2.0 | Monograph: batch-94-2026-04-21/cagrisema-obesity-redefine-1.md | Human review required before clinical use

Graph View

Backlinks